

Review Form 1.7

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_107744
Title of the Manuscript:	The Chinese-Han population carrying wild-type genotypes of SLCO1B1 388A>G, SLCO1B1 521T>C, CYP3A4 1B, CYP3A4 1G, and CYP3A5*3 exhibits a significant alteration in the pharmacokinetics of atorvastatin calcium
Type of the Article	Original Research Article

Review Form 1.7

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <ol style="list-style-type: none"> 1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript) 2. Is the title of the article suitable? (If not please suggest an alternative title) 3. Is the abstract of the article comprehensive? 4. Are subsections and structure of the manuscript appropriate? 5. Do you think the manuscript is scientifically correct? 6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form. <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>	<p>Yes</p> <p>Yes</p> <p>Yes</p> <p>yes</p> <p>Yes</p>	
<p>Minor REVISION comments</p> <ol style="list-style-type: none"> 1. Is language/English quality of the article suitable for scholarly communications? 	<p>Dear Editor, Confidential</p> <p>a) The principal point of this study was to evaluate whether the human gene polymorphism of SLCO1B1 388A>G (rs2306283) affects the clinical pharmacokinetics of AC following the administration of single doses, taking into account the influence of SLCO1B1 521T>C (rs4149056), CYP3A4 1B (rs2740574), CYP3A41G (rs2242480), and CYP3A5*3 (rs776746) genes.</p> <p>b) I think that this study is suitable, after minor revision, to be published onto your prestigious journal.</p> <p>Comments to Author</p> <p>Author is kindly requested to emphasize the current concepts about these issues in the context of recent knowledge and the available literature. This articles should be quoted in the References list.</p> <p>References</p> <ol style="list-style-type: none"> 1. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?. <i>Eur J Med Res.</i> 2023; 28 (1): 381. Published 2023 Sep 27. doi:10.1186/s40001-023-01038-1. 2. Optimization of a solidified micelle formulation for enhanced oral bioavailability of atorvastatin calcium using statistical experimental design. <i>Pharm Dev Technol.</i> 2023; 28 (5): 479-491. doi:10.1080/10837450.2023.2208206. <p>Comments to Author</p> <p>Author is kindly requested to emphasize the current concepts about these issues in the context of recent knowledge and the available literature. This articles should be quoted in the References list.</p> <p>References</p> <ol style="list-style-type: none"> 1. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?. <i>Eur J Med Res.</i> 2023; 28 (1): 381. Published 2023 Sep 27. doi:10.1186/s40001-023-01038-1. 2. Optimization of a solidified micelle formulation for enhanced oral bioavailability of atorvastatin calcium using statistical experimental design. <i>Pharm Dev Technol.</i> 2023; 28 (5): 	

[Review Form 1.7](#)

	479-491. doi:10.1080/10837450.2023.2208206.	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Carmine Finelli
Department, University & Country	Ospedale Cav. R. Apicella, Italy